MX2022012060A - Vectores adenovirales de ave deficientes en la replicacion, sus dise?os y usos. - Google Patents

Vectores adenovirales de ave deficientes en la replicacion, sus dise?os y usos.

Info

Publication number
MX2022012060A
MX2022012060A MX2022012060A MX2022012060A MX2022012060A MX 2022012060 A MX2022012060 A MX 2022012060A MX 2022012060 A MX2022012060 A MX 2022012060A MX 2022012060 A MX2022012060 A MX 2022012060A MX 2022012060 A MX2022012060 A MX 2022012060A
Authority
MX
Mexico
Prior art keywords
vectors
replication
design
aviadenovirus
deficient
Prior art date
Application number
MX2022012060A
Other languages
English (en)
Inventor
Uwe D Staerz
Original Assignee
Greffex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greffex Inc filed Critical Greffex Inc
Publication of MX2022012060A publication Critical patent/MX2022012060A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10251—Methods of production or purification of viral material
    • C12N2710/10252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Las modalidades descritas en la presente se relacionan al diseño, modificación genética y producción de vectores de suministro de gen deficiente en la replicación que están en base a Aviadenovirus. Más particularmente se describe su uso en la transferencia de genes, modificación genética de células y animales, la expresión de proteínas, el desarrollo de vacunas. En algunas modalidades, se describen los diseños y empaquetamiento de vectores de Aviadenovirus parcialmente suprimidos. En otras modalidades, se describen los diseños y empaquetamiento de vectores de Aviadenovirus completamente suprimidos, la propagación de vectores de Aviadenovirus deficientes en la replicación y la característica y modificación genética de células hospederas. En otras modalidades, se describe el uso de tales vectores en la medicina veterinaria.
MX2022012060A 2020-03-29 2021-03-29 Vectores adenovirales de ave deficientes en la replicacion, sus dise?os y usos. MX2022012060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063001361P 2020-03-29 2020-03-29
PCT/US2021/024576 WO2021202331A1 (en) 2020-03-29 2021-03-29 Replication-deficient avian adenoviral vectors, their design and uses

Publications (1)

Publication Number Publication Date
MX2022012060A true MX2022012060A (es) 2023-02-14

Family

ID=77929561

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012060A MX2022012060A (es) 2020-03-29 2021-03-29 Vectores adenovirales de ave deficientes en la replicacion, sus dise?os y usos.

Country Status (7)

Country Link
US (1) US20230140994A1 (es)
EP (1) EP4127192A4 (es)
JP (1) JP2023520611A (es)
CN (1) CN115698306A (es)
CA (1) CA3173714A1 (es)
MX (1) MX2022012060A (es)
WO (1) WO2021202331A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19615803A1 (de) * 1996-04-20 1997-10-23 Boehringer Ingelheim Int CELO-Virus
FR2767335B1 (fr) * 1997-08-14 2001-09-28 Ct Nat D Etudes Veterinaires E Adenovirus aviaire celo recombinant comme vecteur vaccinant
EP1001030A1 (en) * 1998-09-22 2000-05-17 Boehringer Ingelheim International GmbH Recombinant CELO virus and CELO virus DNA
US6841158B1 (en) * 1998-09-22 2005-01-11 Boehringer Ingelheim International Gmbh Recombinant celo virus and celo virus DNA
US6797506B1 (en) * 1999-10-13 2004-09-28 Boehringer Ingelheim International Gmbh Recombinant, replication defective CELO virus and CELO virus DNA
US8871515B2 (en) * 2008-09-17 2014-10-28 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
WO2014006146A1 (en) * 2012-07-04 2014-01-09 Sirion Biotech Gmbh Means and methods to increase adenovirus production
MX2018000353A (es) * 2015-07-10 2018-03-14 Univ Guelph Sistema vector de adenovirus aviar 9 (fadv-9) y metodos asociados.

Also Published As

Publication number Publication date
CN115698306A (zh) 2023-02-03
CA3173714A1 (en) 2021-10-07
JP2023520611A (ja) 2023-05-17
US20230140994A1 (en) 2023-05-11
EP4127192A1 (en) 2023-02-08
WO2021202331A1 (en) 2021-10-07
EP4127192A4 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
Takeyama et al. Plant-based vaccines for animals and humans: recent advances in technology and clinical trials
PE20211581A1 (es) Composiciones para la reduccion de la expresion transgenica especifica de drg
MX2022015081A (es) Variantes de hsd17b13 y usos de las mismas.
CL2020001428A1 (es) Terapia genética para la mucopolisacaridosis iiib.
WO2020079034A3 (en) Intein proteins and uses thereof
HRP20110179T1 (hr) Kimerni adenovirusi za uporabu u liječenju raka
NZ609903A (en) Expression vector for high level expression of recombinant proteins
CN105177045B (zh) 表达人白介素15的重组溶瘤腺病毒及其构建方法
MX2021015433A (es) Vectores ad35 recombinantes y mejoras de la terapia génica relacionadas.
Graham Adenovirus vectors for high-efficiency gene transfer into mammalian cells
BR112017000696A2 (pt) Citomegalovírus humano recombinante (hcmv), sua composição imunogênica, seu uso, polinucleotídeo isolado, célula isolada e método de produção de hcmv com deficiênciade pp71
MX2022012060A (es) Vectores adenovirales de ave deficientes en la replicacion, sus dise?os y usos.
CN102703368A (zh) 一种产角蛋白酶的基因工程菌及其应用
ZA202101298B (en) Multi-targeting nucleic acid constructs composed of multiple oligonucleotides that modulate gene expression through complimentary interactions with targets
Zabala-Pardo et al. RNAi as a tool for weed management: challenges and opportunities
Huynh et al. Generation of Lactococcus lactis capable of coexpressing epidermal growth factor and trefoil factor to enhance in vitro wound healing
Yu et al. Changes in susceptibility to oncolytic vesicular stomatitis virus during progression of prostate cancer
CN102178947A (zh) 一种表达小反刍兽疫病毒h基因的活载体疫苗及制备方法
MX2022012059A (es) Aumento de la produccion de vectores de genetransferencia a base de adenovirus.
JOP20220128A1 (ar) بروتينات gpcr أوبسين خيمرية
Singh et al. Designer probiotics: the next-gen high efficiency biotherapeutics
Lampe et al. Non-complexed chitosan acts as an adjuvant in an influenza A virus protein vaccine
Rabacal et al. A therapeutic vaccine strategy to prevent Pneumocystis pneumonia in an immunocompromised host in a NHP model HIV and Pneumocystis co-infection
Barbosa et al. Performance of straightbred and crossbred Tabapuã cattle on brachiaria pasture in Bahia state
Barry et al. Single-cycle adenoviruses (SC-Ads) as platforms for immunostimulation